# Assembly Biosciences (ASMB) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/ASMB
## Company Profile
- Ticker: ASMB
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Infectious Disease
## Stock Data
- Close: 27.06 USD
- Market cap: 485324452.49999994 USD
- Last updated: 2026-08-12
## Business Overview
### Antiviral Small Molecules
Assembly Biosciences develops oral small-molecule therapies for serious viral diseases. Its portfolio targets viral replication mechanisms with the goal of improving suppression or enabling finite treatment.
### Recurrent Genital Herpes
ABI-5366 and ABI-1179 are helicase-primase inhibitors that have completed Phase 1b studies in recurrent genital herpes. These programs are partnered with Gilead for subsequent development planning.
### Hepatitis Delta Program
ABI-6250 is an oral small-molecule entry inhibitor for chronic hepatitis delta virus infection and has completed chronic toxicology studies supporting Phase 2 development.
## Why The Stock Is Moving

The latest monitored company update is “Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates.” The corresponding closing-price reaction is not yet available.

## Future Catalysts

- Initiation of a Phase 2 study of ABI-6250 in chronic hepatitis delta by the end of 2026.
- Initiation of the Gilead-led Phase 2 GS-1179 study in recurrent genital herpes by the end of 2026.
- Initiation of a Phase 2 ABI-6250 study in cholestatic liver diseases in the first quarter of 2027.

## Recent News
- 2026-08-13 20:00 EST — [Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates](https://biopharmsignal.com/news/ASMB/assembly-biosciences-reports-second-quarter-2026-financial-results-and-recent-up-b8cba017) — Source: Assembly Biosciences
- 2026-05-28 20:05 EST — [Assembly Biosciences Announces Upcoming Investor Conference Presentations](https://biopharmsignal.com/news/ASMB/assembly-biosciences-announces-upcoming-investor-conference-presentations) — Source: Assembly Biosciences
- 2026-05-26 20:05 EST — [Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares](https://biopharmsignal.com/news/ASMB/assembly-biosciences-announces-the-closing-of-its-offering-of-common-stock-and-pre-funded-warrants-and-full-exercise-of-the-underwriters-option-to-purchase-additional-shares) — Source: Assembly Biosciences
- 2026-05-22 11:05 EST — [Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants](https://biopharmsignal.com/news/ASMB/assembly-biosciences-announces-pricing-of-100-million-offering-of-common-stock-and-pre-funded-warrants) — Source: Assembly Biosciences
- 2026-05-22 11:00 EST — [Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases](https://biopharmsignal.com/news/ASMB/assembly-biosciences-announces-expansion-of-abi-6250-clinical-development-into-cholestatic-liver-diseases) — Source: Assembly Biosciences